Trade deal could advance Beijing’s plans to improve pharma IP protections

A long-awaited U.S.-China trade agreement could help China make progress on an initiative to improve patent protections for pharmaceuticals, which have seen little improvement since early plans were released in 2017.

The Office of the U.S. Trade Representative said Friday that the U.S. and China reached a Phase I trade agreement, which includes commitments from China to address Washington’s concerns related to technology transfer and intellectual property.

Under the deal, China will not pressure foreign companies to transfer

Read the full 787 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers